Allie Cummings, B.S., HT(ASCP), Agilent
Predictive biomarker testing to inform treatment decision-making has radically influenced the practice of both pathology and oncology today. As the
treatment scenario evolves, choosing the appropriate biomarker to select the right patients become vital. In this talk we will review the most up-to-date FDA approvals for checkpoint inhibitors and
PD-L1 companion diagnostic assays. We will then compare the different PD-L1 scoring systems (TPS, CPS, IC, TC) and point out the role of clinical validation of PD-L1 assays. Finally, we will look at
the future of cancer targeted therapies and emerging biomarkers.
National Society for Histotechnology3545 Ellicott Mills Dr.Ellicott City, MD 21043
Phone: 443-535-4060Fax: 443-535-4055Email: email@example.com